Related references
Note: Only part of the references are listed.Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment
Angela Schulz et al.
BLOOD (2013)
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
Paolo Strati et al.
BLOOD (2013)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy
John C. Riches et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Asher A. Chanan-Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p
Arvind Arumainathan et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
The Ikaros gene family: Transcriptional regulators of hematopoiesis and immunity
Liza B. John et al.
MOLECULAR IMMUNOLOGY (2011)
Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
Zhengzi Qian et al.
LEUKEMIA RESEARCH (2011)
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
Rosa Lapalombella et al.
BLOOD (2010)
Lenalidomide mode of action: linking bench and clinical findings
Faith Davies et al.
BLOOD REVIEWS (2010)
Examination of the expanding pathways for the regulation of p21 expression and activity
Yong-Sam Jung et al.
CELLULAR SIGNALLING (2010)
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
J. R. Brown et al.
LEUKEMIA (2010)
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
Taimur Sher et al.
LEUKEMIA & LYMPHOMA (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Laure Escoubet-Lozach et al.
CANCER RESEARCH (2009)
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
Georg Aue et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A. Andritsos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
Nionhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells
G Görgün et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Lost in transcription: p21 repression, mechanisms, and consequences
AL Gartel et al.
CANCER RESEARCH (2005)
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
BT Messmer et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
R LeBlanc et al.
BLOOD (2004)
Thalidomide and immunomodulatory drugs as cancer therapy
N Raje et al.
CURRENT OPINION IN ONCOLOGY (2002)
Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells
JB Marriott et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Share Paper
